Header Logo

Connection

SANJAY MATHEW to Depressive Disorder, Treatment-Resistant

Back to Details
This is a "connection" page, showing publications SANJAY MATHEW has written about Depressive Disorder, Treatment-Resistant.
SANJAY MATHEW
Connection Strength
13.025
Depressive Disorder, Treatment-Resistant
  1. Choosing Between Ketamine and Electroconvulsive Therapy for Outpatients With Treatment-Resistant Depression-Advantage Ketamine? JAMA Psychiatry. 2023 12 01; 80(12):1187-1188.
    View in: PubMed
    Score: 0.732
  2. Neural complexity EEG biomarkers of rapid and post-rapid ketamine effects in late-life treatment-resistant depression: a randomized control trial. Neuropsychopharmacology. 2023 10; 48(11):1586-1593.
    View in: PubMed
    Score: 0.701
  3. Pharmacotherapies for Treatment-Resistant Depression: How Antipsychotics Fit in the Rapidly Evolving Therapeutic Landscape. Am J Psychiatry. 2023 03 01; 180(3):190-199.
    View in: PubMed
    Score: 0.695
  4. Replication of distinct trajectories of antidepressant response to intravenous ketamine. J Affect Disord. 2023 01 15; 321:140-146.
    View in: PubMed
    Score: 0.678
  5. Ketamine for treatment of mood disorders and suicidality: A narrative review of recent progress. Ann Clin Psychiatry. 2022 02; 34(1):33-43.
    View in: PubMed
    Score: 0.645
  6. Identification of an optimal dose of intravenous ketamine for late-life treatment-resistant depression: a Bayesian adaptive randomization trial. Neuropsychopharmacology. 2022 04; 47(5):1088-1095.
    View in: PubMed
    Score: 0.637
  7. Habenula Connectivity and Intravenous Ketamine in Treatment-Resistant Depression. Int J Neuropsychopharmacol. 2021 05 18; 24(5):383-391.
    View in: PubMed
    Score: 0.614
  8. Distinct trajectories of antidepressant response to intravenous ketamine. J Affect Disord. 2021 05 01; 286:320-329.
    View in: PubMed
    Score: 0.606
  9. Ketamine Plus Motivational Enhancement Therapy: Leveraging a Rapid Effect to Promote Enduring Change. Am J Psychiatry. 2020 02 01; 177(2):107-109.
    View in: PubMed
    Score: 0.561
  10. ELEctroconvulsive therapy (ECT) vs. Ketamine in patients with Treatment-resistant Depression: The ELEKT-D study protocol. Contemp Clin Trials. 2019 02; 77:19-26.
    View in: PubMed
    Score: 0.519
  11. Serum and plasma brain-derived neurotrophic factor and response in a randomized controlled trial of riluzole for treatment resistant depression. J Affect Disord. 2018 12 01; 241:514-518.
    View in: PubMed
    Score: 0.507
  12. A Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Comparison Design Trial of Adjunctive Riluzole for Treatment-Resistant Major Depressive Disorder. Neuropsychopharmacology. 2017 Dec; 42(13):2567-2574.
    View in: PubMed
    Score: 0.466
  13. Effects of ketamine on explicit and implicit suicidal cognition: a randomized controlled trial in treatment-resistant depression. Depress Anxiety. 2014 Apr; 31(4):335-43.
    View in: PubMed
    Score: 0.374
  14. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry. 2013 Oct; 170(10):1134-42.
    View in: PubMed
    Score: 0.362
  15. Ketamine for treatment-resistant unipolar depression: current evidence. CNS Drugs. 2012 Mar 01; 26(3):189-204.
    View in: PubMed
    Score: 0.324
  16. Comparing the Cognitive Effects of Repeated Intravenous Ketamine and Electroconvulsive Therapy in Patients With Treatment-Resistant Depression: A Secondary Analysis of the ELEKT-D Trial. J Clin Psychiatry. 2025 Sep 03; 86(4).
    View in: PubMed
    Score: 0.207
  17. Effect of augmentation with aripiprazole or augmentation with repetitive transcranial magnetic stimulation versus switching to the antidepressant venlafaxine extended release/duloxetine on cognition: A comparative effectiveness research trial for antidepressant incomplete and non-responders with treatment-resistant depression (ASCERTAIN-TRD). J Affect Disord. 2025 Dec 01; 390:119836.
    View in: PubMed
    Score: 0.204
  18. Comparing the effects of ECT and intravenous ketamine in psychiatric patients with major depressive episodes. J Affect Disord. 2025 Nov 15; 389:119727.
    View in: PubMed
    Score: 0.204
  19. Patient preference effects in a randomized comparative effectiveness study of electroconvulsive therapy and ketamine for treatment resistant depression: An ELEKT-D trial secondary analysis. Psychiatry Res. 2025 May; 347:116411.
    View in: PubMed
    Score: 0.199
  20. Aperiodic (1/f) Neural Activity Robustly Tracks Symptom Severity Changes in Treatment-Resistant Depression. Biol Psychiatry Cogn Neurosci Neuroimaging. 2025 Feb; 10(2):186-194.
    View in: PubMed
    Score: 0.196
  21. Functional connectivity subtypes during a positive mood induction: Predicting clinical response in a randomized controlled trial of ketamine for treatment-resistant depression. J Psychopathol Clin Sci. 2025 Apr; 134(3):228-238.
    View in: PubMed
    Score: 0.194
  22. Efficacy of Deep Brain Stimulation for Treatment-Resistant Depression: Systematic Review and Meta-Analysis. Biol Psychiatry Cogn Neurosci Neuroimaging. 2024 Dec; 9(12):1239-1248.
    View in: PubMed
    Score: 0.193
  23. Cost-effectiveness and threshold analysis of deep brain stimulation vs. treatment-as-usual for treatment-resistant depression. Transl Psychiatry. 2024 Jun 07; 14(1):243.
    View in: PubMed
    Score: 0.190
  24. Ketamine vs Electroconvulsive Therapy for Treatment-Resistant Depression: A Secondary Analysis of a Randomized Clinical Trial. JAMA Netw Open. 2024 06 03; 7(6):e2417786.
    View in: PubMed
    Score: 0.190
  25. Comparative effectiveness research trial for antidepressant incomplete and non-responders with treatment resistant depression (ASCERTAIN-TRD) a randomized clinical trial. Mol Psychiatry. 2024 Aug; 29(8):2287-2295.
    View in: PubMed
    Score: 0.186
  26. Stereo-EEG-guided network modulation for psychiatric disorders: Surgical considerations. Brain Stimul. 2023 Nov-Dec; 16(6):1792-1798.
    View in: PubMed
    Score: 0.184
  27. Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression. N Engl J Med. 2023 06 22; 388(25):2315-2325.
    View in: PubMed
    Score: 0.177
  28. A Novel, Brief, Fully Automated Intervention to Extend the Antidepressant Effect of a Single Ketamine Infusion: A Randomized Clinical Trial. Am J Psychiatry. 2022 12 01; 179(12):959-968.
    View in: PubMed
    Score: 0.168
  29. Deep Brain Stimulation for Depression Informed by Intracranial Recordings. Biol Psychiatry. 2022 08 01; 92(3):246-251.
    View in: PubMed
    Score: 0.159
  30. The effect of single administration of intravenous ketamine augmentation on suicidal ideation in treatment-resistant unipolar depression: Results from a randomized double-blind study. Eur Neuropsychopharmacol. 2021 08; 49:122-132.
    View in: PubMed
    Score: 0.154
  31. Time to relapse after a single administration of intravenous ketamine augmentation in unipolar treatment-resistant depression. J Affect Disord. 2020 01 01; 260:131-139.
    View in: PubMed
    Score: 0.136
  32. Longer-term open-label study of adjunctive riluzole in treatment-resistant depression. J Affect Disord. 2019 11 01; 258:102-108.
    View in: PubMed
    Score: 0.135
  33. Sex differences in response to ketamine as a rapidly acting intervention for treatment resistant depression. J Psychiatr Res. 2019 03; 110:166-171.
    View in: PubMed
    Score: 0.130
  34. Efficacy of intravenous ketamine treatment in anxious versus nonanxious unipolar treatment-resistant depression. Depress Anxiety. 2019 03; 36(3):235-243.
    View in: PubMed
    Score: 0.130
  35. Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD). Mol Psychiatry. 2020 07; 25(7):1592-1603.
    View in: PubMed
    Score: 0.128
  36. A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders. JAMA Psychiatry. 2017 Apr 01; 74(4):399-405.
    View in: PubMed
    Score: 0.115
  37. Neurometabolic Abnormalities in Treatment-Resistant Depression. Am J Psychiatry. 2017 01 01; 174(1):3-5.
    View in: PubMed
    Score: 0.113
  38. Adjunctive Lanicemine (AZD6765) in Patients with Major Depressive Disorder and History of Inadequate Response to Antidepressants: A Randomized, Placebo-Controlled Study. Neuropsychopharmacology. 2017 Mar; 42(4):844-853.
    View in: PubMed
    Score: 0.111
  39. Assessment of the Efficacy and Safety of BMS-820836 in Patients With Treatment-Resistant Major Depression: Results From 2 Randomized, Double-Blind Studies. J Clin Psychopharmacol. 2015 Aug; 35(4):454-9.
    View in: PubMed
    Score: 0.103
  40. Neurocognitive effects of ketamine and association with antidepressant response in individuals with treatment-resistant depression: a randomized controlled trial. Neuropsychopharmacology. 2015 Mar 13; 40(5):1084-90.
    View in: PubMed
    Score: 0.100
  41. Ketamine safety and tolerability in clinical trials for treatment-resistant depression. J Clin Psychiatry. 2015 Mar; 76(3):247-52.
    View in: PubMed
    Score: 0.100
  42. The promise of ketamine for treatment-resistant depression: current evidence and future directions. Ann N Y Acad Sci. 2015 May; 1345:47-58.
    View in: PubMed
    Score: 0.099
  43. Hippocampal volume and the rapid antidepressant effect of ketamine. J Psychopharmacol. 2015 May; 29(5):591-5.
    View in: PubMed
    Score: 0.096
  44. Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol Psychiatry. 2013 Aug 15; 74(4):250-6.
    View in: PubMed
    Score: 0.083
  45. Lack of relationships between ketamine treatment and peripheral neurotrophic and inflammatory factors in a randomized controlled ketamine trial of major depressive disorder. Brain Behav Immun. 2025 Aug; 128:170-178.
    View in: PubMed
    Score: 0.050
  46. Difficult to Treat Depression: Focus on Approach, Algorithms, and Access. J Clin Psychiatry. 2024 Nov 25; 85(4).
    View in: PubMed
    Score: 0.049
  47. Improved implicit self-esteem is associated with extended antidepressant effects following a novel synergistic intervention. Mol Psychiatry. 2024 Nov; 29(11):3431-3439.
    View in: PubMed
    Score: 0.047
  48. Efficacy of Esketamine Augmentation in Major Depressive Disorder: A Meta-Analysis. J Clin Psychiatry. 2020 05 26; 81(4).
    View in: PubMed
    Score: 0.036
  49. Body Mass Index as a Moderator of Treatment Response to Ketamine for Major Depressive Disorder. J Clin Psychopharmacol. 2020 May/Jun; 40(3):287-292.
    View in: PubMed
    Score: 0.036
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.